Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Announces Departure of Chief Legal Officer
Summary
Alnylam Pharmaceuticals, Inc. announced on March 4, 2024, the departure of Indrani L. Franchini, its Executive Vice President, Chief Legal Officer, and Secretary, effective March 1, 2024. As part of her separation agreement, Ms. Franchini will receive severance pay totaling $597,000, a lump sum payment based on her annual incentive plan, healthcare coverage continuation, outplacement services, and reimbursement for legal fees up to $15,000. Additionally, Ms. Franchini will provide consulting services to the company until March 1, 2025, with compensation for hours exceeding ten per month at a rate of $500 per hour. Her unvested equity awards will continue to vest, and stock options will remain exercisable for three months post-consulting period.
Profitelligence Alerts
Get alerts for ALNY
Be first to know when Alnylam Pharmaceuticals Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc. is a pioneering biotechnology company dedicated to transforming the lives of patients through RNA interference (RNAi) therapeutics. This scientific approach allows for innovative treatments that can silence genes responsible for certain diseases, offering a unique angle on genetic therapies. Alnylam's primary focus is on developing therapeutics for genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases, contributing to redefining how these conditions are treated. The company's groundbreaking work in RNAi provides a platform for addressing otherwise untreatable or poorly managed medical conditions, positioning it as a leader in the biotechnology sector. With numerous collaborations, partnerships, and a growing pipeline of therapeutics, Alnylam plays a crucial role in advancing modern medicine and contributing to the evolving landscape of genetic therapeutics. Headquartered in Cambridge, Massachusetts, Alnylam underscores the critical intersection of innovation, medicine, and gene science in the financial and pharmaceutical markets.
Official SEC Documents
Advertisement